Cancer Therapeutics Market Expands as Precision Medicine, Immunotherapy and Antibody-Drug Conjugates Reshape Oncology Care

The global Cancer Therapeutics Market is entering a period of sustained expansion as rising cancer incidence, population aging and advances in precision oncology increase demand for more targeted and individualized treatments. According to Next Move Strategy Consulting, the market was valued at USD 189.79 billion in 2024 and is projected to reach USD 326.05 billion by 2030, representing a 9.4% CAGR from 2025 to 2030. The research points to targeted therapies, immunotherapy, personalized medicine and next-generation antibody-drug conjugates as important areas shaping the industry’s future.

View the Cancer Therapeutics Market Report

Request the FREE Sample Here

Market Growth and Outlook

Cancer therapeutics encompass medicines and treatment approaches used to manage malignant diseases across a broad range of cancer types. The Next Move Strategy Consulting study examines the market by therapy type, cancer type, key drug and end user. Therapy categories include chemotherapy, targeted therapy, immunotherapy, hormonal therapy and other approaches. Cancer categories cover blood, breast, prostate, gastrointestinal, gynecologic, respiratory/lung and other cancers. End users include hospitals, specialty clinics and cancer and radiation therapy centers.

The report uses 2024 as the base year and 2025–2030 as the forecast period. It also evaluates markets across North America, Europe, Asia-Pacific and the Rest of the World.

The scale of the underlying clinical need is substantial. The World Health Organization reports that cancer caused nearly 10 million deaths worldwide in 2024, with lung, breast, colorectal and prostate cancers among the most common by new cases. WHO also notes that many cancers can be cured when detected early and treated effectively, reinforcing the importance of improvements across prevention, diagnosis and treatment.

Rising Cancer Burden Supports Long-Term Treatment Demand

Increasing cancer incidence is a fundamental driver of therapeutics demand. Next Move Strategy Consulting identifies the rising prevalence of cancer and other chronic diseases as a primary growth factor for the industry.

Population aging is another structural influence. The risk of many cancers increases with age, making demographic change an important consideration for pharmaceutical developers, healthcare systems and payers. As the number of older adults grows, demand is expected to remain focused not only on first-line therapies but also on maintenance, combination and later-line treatments.

The broader oncology environment is consequently shifting toward therapies designed around the biological characteristics of individual tumors rather than relying solely on cancer location or conventional treatment categories.

Targeted Therapy and Precision Medicine Gain Importance

Targeted therapy has become a central component of modern oncology. The National Cancer Institute explains that targeted therapies act on proteins that control cancer-cell growth, division and spread and form a foundation of precision medicine. Patients may undergo biomarker testing to determine whether their tumors contain molecular targets for available therapies.

This approach is changing drug development and clinical decision-making. Genomic profiling, biomarker testing and molecular diagnostics can help identify patients more likely to benefit from specific medicines, potentially reducing exposure to therapies that are unlikely to work.

The evolution of precision oncology also includes tumor-agnostic treatment strategies. NCI notes that the 2017 approval of pembrolizumab for tumors with specific genetic characteristics represented an important development because the treatment decision could be based on a molecular feature rather than the tumor’s original anatomical location.

These developments create opportunities for pharmaceutical companies developing targeted agents as well as diagnostic providers supplying companion and biomarker-testing technologies.

Immunotherapy Continues to Broaden the Treatment Landscape

Immunotherapy is another major segment of the Cancer Therapeutics Market. Rather than directly attacking cancer cells in the same manner as traditional cytotoxic chemotherapy, immunotherapies can help the immune system recognize and respond to cancer.

NCI identifies immune checkpoint inhibitors and T-cell transfer therapies among the established classes of cancer immunotherapy. Checkpoint inhibitors work by blocking signals that restrain immune responses, allowing immune cells to attack cancer more effectively in appropriate patients.

NCI’s broader cancer-treatment research program continues to investigate immunotherapies, targeted therapies, cancer vaccines and combinations intended to improve effectiveness while limiting toxicity.

The expanding use of combination regimens is creating a more complex oncology treatment environment. Drug developers must increasingly demonstrate not only whether a therapy works independently, but also how it performs when combined with other treatments.

Antibody-Drug Conjugates Create a New Growth Opportunity

Next-generation antibody-drug conjugates (ADCs) are highlighted by Next Move Strategy Consulting as an important future opportunity. ADCs combine the targeting capabilities of antibodies with cytotoxic payloads, allowing drugs to be directed toward cells expressing particular molecular targets.

Recent regulatory activity illustrates the momentum surrounding this class. In May 2026, the U.S. Food and Drug Administration approved pivekimab sunirine-pvzy, a CD123-directed antibody and alkylating-agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm.

The FDA also approved datopotamab deruxtecan-dlnk in May 2026 for certain patients with unresectable or metastatic triple-negative breast cancer, adding another antibody-drug conjugate to the oncology treatment landscape.

These developments demonstrate how drug developers are pursuing highly specialized therapeutic mechanisms for difficult-to-treat cancers.

Regulatory Activity Reflects Rapid Innovation

The pace of oncology innovation is also visible in the FDA’s expanding list of cancer-treatment approvals. In June 2026, the agency approved a maintenance regimen involving palbociclib for adults with HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy. In July 2026, it granted traditional approval to selpercatinib for certain patients with RET fusion-positive locally advanced or metastatic solid tumors.

Such approvals illustrate an increasingly biomarker-driven treatment environment in which therapies are often linked to specific tumor characteristics, prior treatment history or molecular alterations.

For manufacturers, this creates opportunities for highly differentiated products but also increases the complexity of clinical development, regulatory submissions and post-market evidence generation.

High Treatment Costs Remain a Major Constraint

Despite growing innovation, affordability remains a significant market challenge. Next Move Strategy Consulting identifies the high cost of cancer therapies, including chemotherapy, targeted therapies and immunotherapies, as a restraint that can limit access, particularly in lower-income healthcare systems.

WHO’s 2026 global cancer assessment likewise highlights persistent disparities in access to cancer services between and within countries, including limitations in health-system capacity and the availability of effective treatment.

The economic challenge is becoming more complex as newer precision medicines and advanced biologic therapies often require specialized testing, administration and monitoring. Payers and healthcare systems are therefore paying greater attention to clinical value, cost effectiveness and evidence supporting treatment choices.

North America Leads While Asia-Pacific Expands

North America currently dominates the Cancer Therapeutics Market and is expected to retain its leading position during the forecast period, according to Next Move Strategy Consulting. The report associates the region’s position with the high burden of cancer, advanced healthcare infrastructure and continuing adoption of targeted therapies, immunotherapy and precision medicine.

Asia-Pacific is showing steady growth, supported by government healthcare programs, expanding medical infrastructure and substantial investments in research and development. The report highlights China, India, Japan and other Asian markets as important contributors to regional development.

The regional outlook reflects two simultaneous trends: mature oncology markets are moving toward increasingly specialized treatments, while emerging healthcare systems are expanding access to established cancer therapies and investing in newer treatment technologies.

Competitive Landscape and Industry Development

The competitive environment includes F. Hoffmann-La Roche, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Sanofi, Astellas Pharma, Pfizer, Novartis, Merck KGaA, Eli Lilly, Takeda Pharmaceutical, Regeneron Pharmaceuticals, AstraZeneca, Gilead Sciences and Incyte, among other participants identified by Next Move Strategy Consulting. Product launches and acquisitions are among the strategies shaping the competitive environment.

The report cites several developments illustrating this activity, including AbbVie’s CERVINO Phase 3 program for ABBV-383 in relapsed multiple myeloma, Novartis’ acquisition of Mariana Oncology to strengthen radioligand-therapy capabilities, and Roche’s European authorization of a subcutaneous formulation designed to reduce administration time for an oncology treatment.

“The cancer therapeutics market is moving toward increasingly precise treatment strategies in which molecular biomarkers, immune pathways and targeted delivery technologies influence how therapies are developed and selected,” said a spokesperson at Next Move Strategy Consulting. “At the same time, affordability, equitable access and the ability to demonstrate meaningful clinical value will remain central to the industry’s long-term development.”

Market Report Overview

The Cancer Therapeutics Market report from Next Move Strategy Consulting provides quantitative analysis and forecasts for 2025–2030, including the USD 189.79 billion 2024 market size, USD 326.05 billion 2030 forecast and 9.4% CAGR. The study evaluates chemotherapy, targeted therapy, immunotherapy, hormonal therapy and other treatment categories across blood, breast, prostate, gastrointestinal, gynecologic, respiratory/lung and other cancers. It also examines key drugs, end users, regional markets, market drivers, restraints, opportunities, emerging trends and competitive dynamics.

 

About Next Move Strategy Consulting

Next Move Strategy Consulting is a market research and consulting company providing market intelligence, industry analysis, competitive insights, and strategic research across a wide range of industries and geographic markets.

As cancer incidence remains high and oncology continues to evolve toward biomarker-driven, immune-based and targeted treatment strategies, the therapeutics market will remain a major focus for pharmaceutical companies, biotechnology firms, healthcare providers, investors and policymakers. Continued monitoring will be important as new drug approvals, precision diagnostics, advanced drug-delivery technologies, treatment combinations and affordability considerations shape the future of cancer care through 2030.